Please provide your email address to receive an email when new articles are posted on . Pruritus was reduced by 47.56% as early as day 1 and 95.6% at the final follow-up visit. Fast itch relief was ...

Please provide your email address to receive an email when new articles are posted on . Sustained disease remission occurred in 20% of the study cohort vs. 4% of the placebo group at week 36. 41% of ...

Findings showed 20% of patients treated with dupilumab experienced sustained disease remission at week 36 compared with 4% of those who received placebo. Treatment with dupilumab led to significant ...

Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults with bullous pemphigoid (BP), a chronic and debilitating skin disease primarily affecting the elderly ...

Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases. Persistent, intensely itchy rashes in older adults are often written off as eczema or ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results ...

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for adult patients with bullous pemphigoid ...

Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. On the same day the companies unveiled positive data from a study in chronic spontaneous urticaria (CSU) and a new ...

Some dermatologists might be inclined to simply refer patients with blistering skin diseases, which are relatively rare, to an expert center, but they should not waive the effort to reach a diagnosis ...